AFF1 and leukemia: In vivo, at the subtherapeutic dose of 106 CAR+ cells, CAR-iNKT cell–treated SEM- and CRISPRKMT2A-AFF1 leukemia-bearing mice had a lower disease burden and significantly longer survival than CAR T-cell–treated mice (Figure 4D-G).